Get started

BIOCON

ASLAN Pharmaceuticals Announces $18 Million Private PlacementASLAN Pharmaceuticals Announces $18 Million Private Placement ASLAN today announced that it has entered into a securities purchase agreement to raise gross proceeds of approximately $18 million resulting from the sale of its ordinary shares through a private placement to new institutional investors, Vivo Capital and Surveyor Capital (a Citadel company). the Company will issue an aggregate of 25,568,180 ordinary shares (equivalent to 5,113,636 American Depositary Shares (“ADSs”)) at an equivalent price of $3.52 per ADS, equal to the last closing price of the Company’s ADSs. The Company intends to use the net proceeds from the private placement primarily to advance clinical development of ASLAN004, as well as for general corporate purposes. “These additional resources position us well as we look forward to unblinding the interim data from our ongoing study of ASLAN004 in atopic dermatitis in early March and look towards initiating our phase 2b program later in 2021.” finance.yahoo.com
A
by AlenCiken
Biocon from 5 July 2020Biocon is again showing sign of coming out of consolidation zone though volume is not increasing much MFI is increasing n possible breakout possible monthly analysis 1. at max 15 % increase possible ---> 400 * 1.15 == 460 ( at max ) (highly unlikely ) 2. at max 15 % decrease possible --> 400 * 0.985 == 340 ( at max ) ( highly unlikely ) safe upside setup is to buy at 401 with SL : below swing low with target of 2R option strategy .. Heart of steel --> Million miles journey 1 .Sell 340 PE + Buy 300 PE ( less margin req )
NSE:BIOCONLong
by Trade_with_yash
2